Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours

British Journal of Clinical Pharmacology

Volumn 78, Issue 3, 2014, Pages 524-532

  Leonowens, Cathrine ^a   Pendry, Carolyn ^a   Bauman, John ^a   Young, Graeme C ^b   Ho, May ^a   Henriquez, Frank ^a   Fang, Lei ^a   Morrison, Royce A ^c   Orford, Keith ^a   Ouellet, Daniele ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Comprehensive Clinical Development ^*  (United States)

Author keywords

bioavailability; intravenous; microtracer; pharmacokinetic; trametinib

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; RADIOISOTOPE; TRAMETINIB; TRAMETINIB C 14; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ADULT; ALLOSTERISM; ARTICLE; BLADDER CANCER; CASE REPORT; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SELECTIVITY; ECCHYMOSIS; ESOPHAGUS CANCER; EYE CANCER; FEMALE; FIRST PASS EFFECT; HEADACHE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SOLID TUMOR; VOLUME OF DISTRIBUTION; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; CLINICAL TRIAL; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; NEOPLASMS; ORAL DRUG ADMINISTRATION; TISSUE DISTRIBUTION;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; FEMALE; HALF-LIFE; HUMANS; MALE; MAP KINASE KINASE 1; MAP KINASE KINASE 2; NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDONES; PYRIMIDINONES; TISSUE DISTRIBUTION;

EID: 84906517289     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12373     Document Type: Article

References (22)

1. Abe H, Kikuchi S, Hayakawa K, Iida T, Nagahashi N, Maeda K, Sakamoto J, Matsumoto N, Miura T, Matsumura K, Seki N, Inaba T, Kawasaki H, Yamaguchi T, Kakefuda R, Nanayama T, Kurachi H, Hori Y, Yoshida T, Kakegawa J, Watanabe Y, Gilmartin AG, Richter MC, Moss KG, Laquerre SG,. Discovery of a highly potent and selective MEK inhibitor: GSK1120212 (JTP-74057 DMSO solvate). ACS Med Chem Lett 2011; 2: 320-324.
2. Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkarni SG, Rominger CM, Erskine S, Fisher KE, Yang J, Zappacosta F, Annan R, Sutton D, Laquerre SG,. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 2011; 17: 989-1000.
3. Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, Peddareddigari VG, Lebowitz PF, Le NT, Burris HAI, Messersmith WA, O'Dwyer PJ, Kim KB, Flaherty K, Bendell JC, Gonzalez R, Kurzrock R, Fecher LA,. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13: 782-789.
4. Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P, Gonzalez R, Ott PA, Long GV, Gardner OS, Ouellet D, Xu Y, DeMarini DJ, Le NT, Patel K, Lewis KD,. Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013; 31: 482-489.
5. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D,. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 107-114.
6. Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock R, Flaherty K, Burris HAI, Messersmith WA,. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13: 773-781.
7. Denton CL, Minthorn E, Carson SW, Young GC, Richards-Peterson LE, Botbyl J, Han C, Morrison RA, Blackman SC, Ouellet D,. Concomitant oral and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with BRAF V600 mutation-positive solid tumors. J Clin Pharmacol 2013; 53: 955-961.
8. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER). FDA guidance for industry: bioavailability and bioequivalence studies for orally administered drug products-general considerations. 2003. Available at http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf (last accessed 26 February 2013).
9. European Medicines Agency (EMEA), Committee for Medicinal Products for Human Use (CHMP). Position paper on non-clinical safety studies to support clinical trials with a single microdose, 2004. 2013. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/ general-content-000400.jsp&mid=WC0b01ac0580029570 (last accessed 26 February 2013).
10. Hoffmann E, Wald J, Lavu S, Roberts J, Beaumont C, Haddad J, Elliott P, Westphal C, Jacobson E,. Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man. Br J Clin Pharmacol 2013; 75: 186-196.
11. Vasist Johnson LS, Young MA, Stevens LA, Cozens SJ, Collier J, Robertson DC, Dukes GE,. A microtracer study of GSK962040, a motilin receptor agonist, to support dosing regimens in the critical care setting. Clin Pharmacol Ther 2013; 93: S80.
12. Gao L, Li J, Kasserra C, Song Q, Arjomand A, Hesk D, Chowdhury SK,. Precision and accuracy in the quantitative analysis of biological samples by accelerator mass spectrometry: application in microdose absolute bioavailability studies. Anal Chem 2011; 83: 5607-5616.
13. Xu XS, Dueker SR, Christopher LJ, Lohstroh PN, Keung CF, Cao KK, Bonacorsi SJ, Cojocaru L, Shen JX, Humphreys WG, Stouffer B, Arnold ME,. Overcoming bioanalytical challenges in an onglyza intravenous [(14)C]microdose absolute bioavailability study with accelerator MS. Bioanalysis 2012; 4: 1855-1870.
14. 14C- microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin. Br J Clin Pharmacol 2013; 75: 763-768.
15. Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Houston B, Oosterhuis B, Bjerrum OJ, Rowland M, Garner C,. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Eur J Pharm Sci 2010; 40: 125-131.
16. Sarapa N, Hsyu PH, Lappin G, Garner RC,. The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers. J Clin Pharmacol 2005; 45: 1198-1205. (Pubitemid 41361920)
17. Zhou XJ, Garner RC, Nicholson S, Kissling CJ, Mayers D,. Microdose pharmacokinetics of IDX899 and IDX989, candidate HIV-1 non-nucleoside reverse transcriptase inhibitors, following oral and intravenous administration in healthy male subjects. J Clin Pharmacol 2009; 49: 1408-1416.
18. Young GC, Corless S, Felgate CC, Colthup PV,. Comparison of a 250 kV single-stage accelerator mass spectrometer with a 5 MV tandem accelerator mass spectrometer-fitness for purpose in bioanalysis. Rapid Commun Mass Spectrom 2008; 22: 4035-4042.
19. Rowland M, Tozer TN,. Clinical Pharmacokinetics: Concepts and Applications, 2nd ed edn. Philadelphia, PA: Lea & Febiger, 1989.
20. Kassir N, Mouksassi M, Cox DS, DeMarini DJ, Gardner OS, Sherman L, Crist WA, Ouellet D,. Population pharmacokinetics (PK) of trametinib (GSK1120212), a MEK inhibitor, in subjects with cancer. Clin Pharmacol Ther 2013; 93: S69.
21. Cox DS, Papdopoulos KP, Fang L, Bauman J, LoRusso P, Tolcher AW, Patnaik A, Pendry C, Orford K, Ouellet D,. Evaluation of the effects of food on the single-dose pharmacokinetics of trametinib, a first-in-class MEK inhibitor, in patients with cancer. J Clin Pharmacol 2013; 53: 946-954.
22. Ho MY, Morris MJ, Pirhalla JL, Bauman JW, Pendry CB, Orford KW, Morrison RA, Cox DS,. Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers. Xenobiotica 2013; 44: 352-368.